Ana M. Castejón

740 total citations
25 papers, 552 citations indexed

About

Ana M. Castejón is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Social Psychology. According to data from OpenAlex, Ana M. Castejón has authored 25 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Social Psychology. Recurrent topics in Ana M. Castejón's work include Neuroendocrine regulation and behavior (4 papers), Hormonal Regulation and Hypertension (4 papers) and Stress Responses and Cortisol (3 papers). Ana M. Castejón is often cited by papers focused on Neuroendocrine regulation and behavior (4 papers), Hormonal Regulation and Hypertension (4 papers) and Stress Responses and Cortisol (3 papers). Ana M. Castejón collaborates with scholars based in United States, Slovakia and Venezuela. Ana M. Castejón's co-authors include Luigi X. Cubeddu, Ján Bakoš, Anna B. Alfieri, Irene Hoffmann, Zuzana Bačová, Daniela Ostatníková, Stephen G. Grant, Richard C. Deth, Malav Trivedi and Luís Hernández and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, The FASEB Journal and Biochemical and Biophysical Research Communications.

In The Last Decade

Ana M. Castejón

25 papers receiving 536 citations

Peers

Ana M. Castejón
Kamal Albarazanji United States
Enrique F. Castillo Mexico
Martin Gajdoš Slovakia
Karim Zouaoui Boudjeltia Belgium
Katya B. Rubinow United States
Maurizio Nordio Italy
Kerttu Irjala Finland
Valéria Ernestânia Chaves Brazil
Aernout D. van Haarst Netherlands
Mohammad Hadi Gharedaghi United States
Kamal Albarazanji United States
Ana M. Castejón
Citations per year, relative to Ana M. Castejón Ana M. Castejón (= 1×) peers Kamal Albarazanji

Countries citing papers authored by Ana M. Castejón

Since Specialization
Citations

This map shows the geographic impact of Ana M. Castejón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana M. Castejón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana M. Castejón more than expected).

Fields of papers citing papers by Ana M. Castejón

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana M. Castejón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana M. Castejón. The network helps show where Ana M. Castejón may publish in the future.

Co-authorship network of co-authors of Ana M. Castejón

This figure shows the co-authorship network connecting the top 25 collaborators of Ana M. Castejón. A scholar is included among the top collaborators of Ana M. Castejón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana M. Castejón. Ana M. Castejón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Omidian, Hossein, et al.. (2025). Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals. 18(1). 127–127. 13 indexed citations
2.
Ansari, Rais A., et al.. (2024). Advanced nanoscale delivery systems for mRNA-based vaccines. Biochimica et Biophysica Acta (BBA) - General Subjects. 1868(3). 130558–130558. 8 indexed citations
3.
Deth, Richard C., et al.. (2024). Metformin-induced oxidative stress inhibits LNCaP prostate cancer cell survival. Molecular Biology Reports. 51(1). 729–729. 5 indexed citations
4.
Clark, Michelle A., et al.. (2024). Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review. Cancer Chemotherapy and Pharmacology. 94(1). 1–23. 1 indexed citations
5.
Castejón, Ana M., et al.. (2021). Improving Antioxidant Capacity in Children With Autism: A Randomized, Double-Blind Controlled Study With Cysteine-Rich Whey Protein. Frontiers in Psychiatry. 12. 669089–669089. 13 indexed citations
6.
Pakchin, Parvin Samadi, Ali Movafeghi, Jaleh Barar, et al.. (2021). Impacts of oxidants and antioxidants on the emergence and progression of Alzheimer's disease. Neurochemistry International. 153. 105268–105268. 33 indexed citations
7.
Zukerman, Ryan, Rebecca S. Eshraghi, Jeenu Mittal, et al.. (2019). Nutritional interventions for autism spectrum disorder. Nutrition Reviews. 78(7). 515–531. 81 indexed citations
8.
Bačová, Zuzana, F. Puerta, Mohammed M. Alanazi, et al.. (2018). Projection length stimulated by oxytocin is modulated by the inhibition of calcium signaling in U-87MG cells. Journal of Neural Transmission. 125(12). 1847–1856. 8 indexed citations
9.
Gažová, Andrea, et al.. (2018). Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women. Journal of Traditional and Complementary Medicine. 9(2). 138–142. 12 indexed citations
10.
Puerta, F., Mohammed M. Alanazi, Zuzana Bačová, et al.. (2016). Downregulation of Oxytocin Receptor Decreases the Length of Projections Stimulated by Retinoic Acid in the U-87MG Cells. Neurochemical Research. 42(4). 1006–1014. 12 indexed citations
11.
Bakoš, Ján, Zuzana Bačová, Stephen G. Grant, Ana M. Castejón, & Daniela Ostatníková. (2015). Are Molecules Involved in Neuritogenesis and Axon Guidance Related to Autism Pathogenesis?. NeuroMolecular Medicine. 17(3). 297–304. 50 indexed citations
12.
Castejón, Ana M., et al.. (2007). Upregulation of Angiotensin II-AT1 Receptors During Statin Withdrawal in Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology. 50(6). 708–711. 17 indexed citations
13.
Villar, David, et al.. (2007). Regulation of c-fos, c-jun and c-myc Gene Expression by Angiotensin II in Primary Cultured Rat Astrocytes: Role of ERK1/2 MAP Kinases. Neurochemical Research. 33(3). 545–550. 30 indexed citations
14.
Tristano, Antonio G., et al.. (2006). Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochemical and Biophysical Research Communications. 353(1). 11–17. 19 indexed citations
15.
Castejón, Ana M., et al.. (2006). NAD(P)H oxidase p22phox gene C242T polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. Journal of Human Hypertension. 20(10). 772–779. 20 indexed citations
16.
Laval, Guillaume, Irene Hoffmann, Ana M. Castejón, et al.. (2005). CYP11B2-CYP11B1 Haplotypes Associated with Decreased 11β-Hydroxylase Activity. The Journal of Clinical Endocrinology & Metabolism. 90(2). 1220–1225. 21 indexed citations
17.
Hoffmann, Irene, et al.. (2004). Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. Journal of Human Hypertension. 19(3). 233–240. 61 indexed citations
18.
Castejón, Ana M., et al.. (2002). Differential blood pressure effects of oral glucose and intravenous L-arginine in healthy lean normotensive and obese hypertensive subjects. Journal of Human Hypertension. 16(S1). S133–S136. 11 indexed citations
19.
Castejón, Ana M., Ximena Páez, Luís Hernández, & Luigi X. Cubeddu. (1999). Use of Intravenous Microdialysis to Monitor Changes in Serotonin Release and Metabolism Induced by Cisplatin in Cancer Patients: Comparative Effects of Granisetron and Ondansetron. Journal of Pharmacology and Experimental Therapeutics. 291(3). 960–966. 34 indexed citations
20.
Valencia, Eulalia, et al.. (1994). [Serum activity of the lactate dehydrogenase enzyme in patients with human immunodeficiency virus infection].. PubMed. 11(12). 580–3. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kamal Albarazanji Breakdown of academic impact, for papers by Enrique F. Castillo Breakdown of academic impact, for papers by Martin Gajdoš Breakdown of academic impact, for papers by Karim Zouaoui Boudjeltia Breakdown of academic impact, for papers by Katya B. Rubinow Breakdown of academic impact, for papers by Maurizio Nordio Breakdown of academic impact, for papers by Kerttu Irjala Breakdown of academic impact, for papers by Valéria Ernestânia Chaves Breakdown of academic impact, for papers by Aernout D. van Haarst Breakdown of academic impact, for papers by Mohammad Hadi Gharedaghi
Rankless by CCL
2026